■ 学術雑誌
|
原著
|
|
1.
|
池田慧、清家正博、小澤雄一、花田満美、長谷川一男、川崎由華、伊藤ゆり、池田徳彦：
患者・医師アンケート2023から見えてくる、肺がん治療と仕事の両立支援のいま.
肺癌
65
(2)
：80
-90
, 2025
|
|
2.
|
Felip E, Rojas CI, Schenker M, Kowalski DM, Casarini IA, Csöszi T, Şendur
MAN, Martins J, Blanco AC, Wang CC, Song X, Ramirez Fallas RAL, Yoshioka H, Nair
S, Wang M, Deng X, Lala M, Eiras R, Takahashi T.：
Subcutaneous Versus Intravenous Pembrolizumab, in Combination With Chemotherapy, for Treatment of Metastatic Non-Small Cell Lung Cancer: The Phase 3 3475A-D77 Trial.
Annals of oncology
36
(7)
：775
-785
, 2025
|
|
3.
|
Nishioka N, Hata T, Yamada T, Goto Y, Amano A, Negi Y, Watanabe S, Furuya N,
Oba T, Ikoma T, Nakao A, Tanimura K, Taniguchi H, Yoshimura A, Fukui T, Murata
D, Kaira K, Shiotsu S, Hibino M, Okada A, Chihara Y, Kawachi H, Kijima T,
Takayama K.：
Impact of TTF-1 Expression on the Prognostic Prediction of Patients with Non-Small Cell Lung Cancer with PD-L1 Expression Levels of 1% to 49%, Treated with Chemotherapy vs. Chemoimmunotherapy: A Multicenter, Retrospective Study.
Cancer research and treatment
57
(2)
：412
-421
, 2025
|
|
4.
|
Kanda S, Niho S, Kurata T, Nomura S, Kawashima Y, Iwama E, Yokoyama T,
Watanabe Y, Tanaka H, Fujiwara Y, Zenke Y, Azuma K, Taniguchi H, Toyozawa R,
Hosomi Y, Murakami H, Hara S, Bessho A, Yamamoto N, Ohe Y.：
Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-doublet Chemotherapy for Non-small Cell Lung Cancer Harboring EGFR Mutation.
Clinical cancer research
31
(12)
：2317
-2326
, 2025
|
|
5.
|
Hata T, Yamada T, Goto Y, Amano A, Negi Y, Watanabe S, Furuya N, Oba T, Ikoma
T, Nakao A, Tanimura K, Taniguchi H, Yoshimura A, Fukui T, Murata D, Kaira K,
Shiotsu S, Hibino M, Okada A, Chihara Y, Kawachi H, Kijima T, Takayama K.：
Regimen Selection for Chemoimmunotherapy in Nonsquamous Non-Small Cell Lung Cancer with Low PD-L1 Expression: A Multicenter Retrospective Cohort Study.
Clinical lung cancer
26
(3)
：e190
-e198.e4
, 2025
|
|
6.
|
Ishida Y, Ikeda S, Harada T, Sakakibara-Konishi J, Yokoo K, Kikuchi H, Iwasawa T, Misumi T, Konno S, Ogura T.：
High incidence of immune checkpoint inhibitor-induced pneumonitis in patients with non-small cell lung cancer and interstitial pneumonia, regardless of honeycomb lung or forced vital capacity: results from a multicenter retrospective study.
International Journal of Clinical Oncology
：Online ahead of print
, 2025
|
|
7.
|
Katsushima U, Kurose S, Fukushima T, Nakano J, Ogushi N, Fujii K, Nagata Y,
Kamisako K, Okuno Y, Okazaki Y, Nakanishi K, Yoshida K, Ikoma T, Takeyasu Y,
Yamanaka Y, Yoshioka H, Hase K, Kurata T.：
Impact of time to treatment initiation on the development of cachexia and clinical outcomes in lung cancer.
Japanese journal of clinical oncology
55
(5)
：505
-513
, 2025
|
|
8.
|
Miura S, ,Tanaka H, Misumi T, Yoshioka H, Tokito T, Fukuhara T, Sato Y, Shiraishi Y, Naoki K, Akamatsu H, Yamaguchi O, Furuya N, Kurata T, Kato T, Ikeda S, Horinouchi H, Ichihara E, Mori M, Takiguchi Y, Tanaka K, Goto Y, Okamoto H：
A pragmatic randomized study of afatinib vs. chemotherapy for non-small-cell lung cancer patients with uncommon epidermal growth factor receptor mutations: ACHILLES/TORG1834.
Journal of Clinical Oncology
43
(18)
：2049
-2058
, 2025
|
|
9.
|
Miura S, Tanaka H, Misumi T, Yoshioka H, Tokito T, Fukuhara T, Sato Y,
Shiraishi Y, Naoki K, Akamatsu H, Yamaguchi O, Yokoyama T, Kuyama S, Nishino K,
Furuya N, Kurata T, Kato T, Ikeda S, Horinouchi H, Ichihara E, Mori M, Takiguchi
Y, Tanaka K, Goto Y, Okamoto H; Thoracic Oncology Research Group and all
ACHILLES investigators.：
Pragmatic Randomized Study of Afatinib Versus Chemotherapy for Patients With Non-Small Cell Lung Cancer With Uncommon Epidermal Growth Factor Receptor Mutations: ACHILLES/TORG1834.
Journal of clinical oncology
43
(18)
：2049
-2058
, 2025
|
|
10.
|
Fukui T, Mamesaya N, Takahashi T, Kishi K, Yoshizawa T, Tokito T, Azuma K,
Morikawa K, Igawa S, Okuma Y, Yamanaka Y, Hosokawa S, Kasai T, Masubuchi K,
Nakamichi S, Aga M, Sasaki J, Kada A, Saito AM, Naoki K, Okamoto H; Thoracic
Oncology Research Group (TORG).：
A Prospective Phase II Trial of First-line Osimertinib for Patients with EGFR Mutation-positive Non-small Cell Lung Cancer and Poor Performance Status (OPEN/TORG2040).
Journal of thoracic oncology
20
(5)
：665
-675
, 2025
|
|
11.
|
Akamatsu H, Sakata S, Azuma K, Yoshioka H, Uemura T, Tsuchiya-Kawano Y, Esumi
S, Kurosaki T, Sato Y, Sakamoto T, Ninomiya K, Toyozawa R, Yoneshima Y, Shukuya
T, Kozuki T, Watanabe K, Daga H, Kato T, Takahashi T, Osuga M, Koh Y, Morita S,
Yamamoto N.：
A Single-Arm Phase 2 Study of Sotorasib Plus Carboplatin and Pemetrexed in Patients With Advanced Nonsquamous NSCLC With KRAS G12C Mutation (WJOG14821L, SCARLET).
Journal of thoracic oncology
20
(6)
：775
-785
, 2025
|
|
12.
|
Ikeda S, Ogura T, Miyaoka E, Sekine I, Shukuya T, Takayama K, Inoue A, Okamoto I, Seike M, Takahashi K, Yamamoto N, Yotsukura M, Watanabe S, Shintani Y.：
Survival Benefit and Potential Markers of Chemotherapy for Elderly and Poor Performance Status Patients with Advanced Non-Small Cell Lung Cancer: Results from the Japanese Joint Committee of Lung Cancer Registry Database.
Lung Cancer
200
：108102
, 2025
|
|
13.
|
Tachihara M, Shoda H, Akazawa Y, Ota T, Oki M, Sato Y, Sugawara S, Ikeda S, Yokoyama T, Kaneda H, Itoh S, Bessho A, Katakami N, Morita S, Nakagawa K, Okamoto I, Yamamoto N.：
Durvalumab plus irinotecan + cisplatin for untreated extensive-stage small cell lung cancer: REBORN, phase II study (WJOG13520L).
Lung Cancer
Epub ahead of print
, 2025
|
|
14.
|
Byoung Chul Cho, Hidetoshi Hayashi, Jong-Seok Lee, Se-Hoon Lee, Pongwut Danchaivijitr, Ying Cheng, Baogang Liu, Adlinda Alip, Hailin Xiong, Soon Hin How, Gee-Chen Chang, James Chih-Hsin Yang, Hiroshige Yoshioka, Mehmet Ali Nahit Şendur, Kumar Prabhash, Koichi Azuma, Yun-Gyoo Lee, Chien-Chung Lin, Shingo Matsumoto, Patrapim Sunpaweravong, Yichuan Xia, Melissa Martinez, Joshua M Bauml, Seema Sethi, Shun Lu：
Amivantamab plus lazertinib versus osimertinib as first-line treatment in EGFR-mutated advanced non-small cell lung cancer: MARIPOSA Asian subset.
Lung cancer (Amsterdam, Netherlands)
204
：108496
, 2025
|
|
15.
|
Kenji Morimoto, Tadaaki Yamada, Naoki Furuya, Hisashi Tanaka, Akihiro Yoshimura, Tomohiro Oba, Makoto Hibino, Takahito Fukuda, Yasuhiro Goto, Akira Nakao, Shinsuke Ogusu, Yuta Okazaki, Taishi Harada, Takayo Ota, Ken Masubuchi, Koji Mikami, Tae Hata, Shoki Matsumoto, Ryoichi Honda, Koji Date, Yusuke Chihara, Hayato Kawachi, Koichi Takayama：
Impact of EGFR Mutation Subtypes on Response to Chemoimmunotherapy and Chemotherapy in Non-Small-Cell Lung Cancer After EGFR-TKI Failure.
Targeted oncology
20
(3)
：531
-541
, 2025
|
|
総説及び解説
|
|
1.
|
藤本 一志，池田 慧：
【あらためて考える—肺癌周術期治療 課題とこれから】Ⅵ. ドライバー遺伝子変異/転座を有する非小細胞肺癌の周術期治療 EGFR遺伝子変異陽性非小細胞肺癌に対する周術期治療.
呼吸器ジャーナル
73
(1)
：101
-110
, 2025
|
|
2.
|
池田慧、立石和也、田中健介：
高度に専門化する肺がん診療にどんと構えるために チーム医療、共同意思決定、薬の選び方.
内科
153
(2)
：303
-310
, 2025
|
|
